Edwards Lifesciences Corp
EW
Market Cap$45.88B
Close$
Earnings Call Q1 2025
April 23, 2025 - AI Summary
Strong Q1 Performance: Edwards Lifesciences reported first-quarter sales of $1.041 billion, reflecting an 8% year-over-year growth. This was driven by increased adoption of TAVR (Transcatheter Aortic Valve Replacement) technology and the expanding TMTT (Transcatheter Mitral and Tricuspid Therapies) portfolio.
Updated TMTT Sales Guidance: The company raised its 2025 sales guidance for TMTT to $530-$550 million due to strong momentum and favorable foreign exchange rates. This represents a significant growth of approximately 60% from the previous year, indicating successful adoption of innovative technologies like Pascal and Evoque.
TAVR Growth Outlook: Edwards maintained its full-year TAVR sales growth guidance at 5%-7% and highlighted potential expansions with upcoming indication approvals for treating asymptomatic patients. The expectation is that the approval will happen in the second quarter, which could contribute to future growth.
Exclusive for Stockcircle Pro members
Sign up
$33.82
56.6% downside
Current Fair Value
56.6% downsideOvervalued by 56.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $45.88 Billion |
|---|---|
| Enterprise Value | $43.97 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $6.98 |
| Beta | 1.13 |
| Outstanding Shares | 586,900,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 10.98 |
|---|---|
| PEG | 633.46 |
| Price to Sales | 8.65 |
| Price to Book Ratio | 4.58 |
| Enterprise Value to Revenue | 7.94 |
| Enterprise Value to EBIT | 26.7 |
| Enterprise Value to Net Income | 10 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Edwards Lifesciences Corp
CEO: Michael Mussallem